Skip to main content

Advertisement

SpringerLink
Log in

A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC.

Methods

We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC.

Results

From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand–foot syndrome was more common in the XP group, no patients experienced grade 3 or more.

Conclusions

Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. International Agency for Research on Cancer; GLOBOCAN 2008: http://www-dep.iarc.fr/CancerMondial.htm

  2. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  3. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

    Article  PubMed  CAS  Google Scholar 

  4. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215–221

    Article  PubMed  CAS  Google Scholar 

  5. Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666–673

    Article  PubMed  Google Scholar 

  6. Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28:1547–1553

    Article  PubMed  CAS  Google Scholar 

  7. Sakata Y, Ohtsu A, Horikoshi N et al (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715–1720

    Article  PubMed  CAS  Google Scholar 

  8. Koizumi W, Kurihara M, Nakano S et al (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191–197

    Article  PubMed  CAS  Google Scholar 

  9. Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063–1069

    Article  PubMed  CAS  Google Scholar 

  10. Okines AF, Norman AR, McCloud P et al (2009) Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 20:1529–1534

    Article  PubMed  CAS  Google Scholar 

  11. National Comprehensive Cancer Network : NCCN clinical practice guidelines in Oncology, Gastric Cancer V.2.2011. (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp)

  12. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  PubMed  CAS  Google Scholar 

  13. Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clinical Oncol 29:3968–3976. doi:10.1200/JCO.2011.36.2236

    Article  CAS  Google Scholar 

  14. Ajani JA, Faust J, Ikeda K et al (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23:6957–6965

    Article  PubMed  CAS  Google Scholar 

  15. Daigo S, Takahashi Y, Fujieda M et al (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12:299–306

    Article  PubMed  CAS  Google Scholar 

  16. Goh BC, Soo RA, Lim S et al (2008) Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. J Clin Oncol 26:113s (Abstr 2507)

    Google Scholar 

  17. Sakamoto J, Chin K, Kondo K et al (2006) Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs 17:231–236

    Article  PubMed  CAS  Google Scholar 

  18. Lee JL, Kang YK, Kang HJ et al (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99:584–590

    Article  PubMed  CAS  Google Scholar 

  19. Yamada Y, Yamamoto S, Ohtsu A et al (2009) Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. J Clin Oncol 27:15s (Abstr 4535)

    Google Scholar 

  20. Ichikawa W, Takahashi T, Suto K et al (2004) Gene expressions for thymidylate synthase (TS), orotate phosphoribosyltransferase (OPRT), and thymidine phosphorylase (TP), not dihydropyrimidine dehydrogenase (DPD), influence outcome of patients (pts) treated with S-1 for gastric cancer (GC). J Clin Oncol (Meeting Abstracts) 2:4050

    Google Scholar 

  21. Napieralski R, Ott K, Kremer M et al (2005) Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11:3025–3031

    Article  PubMed  CAS  Google Scholar 

  22. Salonga D, Danenberg KD, Johnson M et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327

    PubMed  CAS  Google Scholar 

  23. Koizumi W, Okayasu I, Hyodo I et al (2008) Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs 19:819–824

    Article  PubMed  CAS  Google Scholar 

  24. Koizumi W, Saigenji K, Nakamaru N et al (1999) Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56:215–222

    Article  PubMed  CAS  Google Scholar 

  25. Takiguchi N, Ishii R, Koda K et al (2003) Thymidine phosphorylase expression correlates with malignant potential and anti-tumor effect of doxifluridine on gastric cancer: multivariate analysis for adjuvant chemotherapy doxifluridine vs. 5-fluorouracil. Oncol Rep 10:1105–1111

    PubMed  CAS  Google Scholar 

  26. Meropol NJ, Gold PJ, Diasio RB et al (2006) Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:4069–4077

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None of the authors have financial or personal conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan

    Kohei Shitara, Chihiro Kondo, Daisuke Takahari, Takashi Ura & Kei Muro

  2. Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Japan

    Akira Sawaki, Masahiro Tajika & Yasumasa Niwa

  3. Nagoya Daini Red Cross Hospital, Nagoya, Japan

    Akira Sawaki

  4. Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan

    Keitaro Matsuo

Authors
  1. Kohei Shitara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Sawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keitaro Matsuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chihiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daisuke Takahari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Ura
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Tajika
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasumasa Niwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kei Muro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kohei Shitara.

About this article

Cite this article

Shitara, K., Sawaki, A., Matsuo, K. et al. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol 18, 539–546 (2013). https://doi.org/10.1007/s10147-012-0416-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-012-0416-6

Keywords

Search

Navigation